Overview

Efficacy and Safety Study of Avastin to Treat Neovascularisation of the Cornea

Status:
Completed
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
Corneal newvessels may arise from a fan of pathologies, inducing long-standing corneal opacification requiring keratoplasty. These last years, VEGF inhibitors have been designed to reduce newascularization induced by gastric cancer or age-related macular degeneration. A few reports have been published showing the interest of VEGF inhibitors to treat corneal newvessels, but no randomized study has been achieved to date. This study is designed to assess the efficacy of Bevacizumab, a VEGF inhibitor monoclonal antibody, to reduce the surface of corneal newvessels in when compared to placebo
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Limoges
Treatments:
Bevacizumab